Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Sahebjam, Solmaz, Forsyth, Peter A, Tran, Nam D, Arrington, John A, Macaulay, Robert, Etame, Arnold B, Walko, Christine M, Boyle, Theresa, Peguero, Edwin N, Jaglal, Michael, Mokhtari, Sepideh, Enderling, Heiko, Raghunand, Natarajan, Gatewood, Tyra, Long, Wendy, Dzierzeski, Jennifer L, Evernden, Brittany, Robinson, Timothy, Wicklund, Melissa C, Kim, Sungjune, Thompson, Zachary J, Chen, Dung-Tsa, Chinnaiyan, Prakash, Yu, Hsiang-Hsuan Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8041351/
https://ncbi.nlm.nih.gov/pubmed/33173935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa260
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares